Date: June 2026
The RACGP’s response highlighted the importance of maintaining flexibility in fee waiver arrangements, particularly for repurposed medicines, off‑patent products, and treatments for rare or low‑volume conditions where commercial incentives may be limited. This flexibility can help support patient access to beneficial therapies and emerging evidence.
Draft 2026-27 Cost Recovery Implementation Statement for listing medicines on the Pharmaceutical Benefits Scheme and designated vaccines on the National Immunisation Program
Advertising